

8 May 2017

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

To,
National Stock Exchange of India Limited
Exchange Plaza,
Bandra – Kurla Complex,
Bandra (E), Mumbai - 400 051

Scrip Code: 524669

Symbol: HESTERBIO

Respected Sir / Madam,

Subject: Outcome of Board Meeting held today and Submission of Audited Standalone and Consolidated Financial Results for the quarter and year ended on 31 March 2017

Start Time: 10.45 am**Conclusion Time: 11.25 am**

This is in reference to our letter dated 1 May 2017 intimating the date of the Board Meeting for consideration of the Audited Standalone and Consolidated Financial Results for the quarter and year ended on 31 March 2017.

Pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board of Directors, in their Meeting held today, have approved the Audited Standalone and Consolidated Financial Results for the quarter and year ended on 31 March 2017.

Kindly note that Board of Directors has recommended final dividend of 23% that is INR 2.30 per equity share for the financial year 2016-17, subject to approval of members in the ensuing Annual General Meeting.

We attach herewith:

- 1) The approved Audited Standalone and Consolidated Financial Results along with Form - A under Regulations 33 of SEBI (LODR) Regulations, 2015 and Auditors Report.
- 2) Press Release issued in this regard

We are arranging to publish these results in the newspaper as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

You are requested to take the above information on your record.

**Sincerely,
For Hester Biosciences Limited**



**Rajiv Gandhi
CEO & Managing Director**